Osteoporosis and bone fractures in patients with diabetes mellitus

Diabetologia Doswiadczalna i Kliniczna

Volumn 8, Issue 2, 2008, Pages 63-67

  Milczarczyk, Alicja ^a,c   Franek, Edward ^a,b  

^a CENTRAL CLINICAL HOSPITAL   (Poland)

^b POLISH ACADEMY OF SCIENCES   (Poland)

^c Diabetological Outpatient Clinic

Author keywords

Bone fractures; Bone mineral density (BMD); Diabetes mellitus; Osteoporosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALENDRONIC ACID; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIPARKINSON AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; INSULIN; LEPTIN; LOOP DIURETIC AGENT; METFORMIN; OPIATE; ORAL ANTIDIABETIC AGENT; PARATHYROID HORMONE[1-34]; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

ARM FRACTURE; AUTOIMMUNE DISEASE; AUTONOMIC NEUROPATHY; BONE DENSITY; BONE MASS; CALCIUM BALANCE; CALCIUM INTAKE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DIABETIC DIET; DISEASE COURSE; DISEASE DURATION; DNA POLYMORPHISM; DRUG CONTRAINDICATION; FALLING; FEMUR NECK FRACTURE; FOOT FRACTURE; FOREARM FRACTURE; FRACTURE; GLYCEMIC CONTROL; HEREDITY; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; RISK FACTOR; SPINE FRACTURE; VITAMIN D DEFICIENCY;

EID: 51949096882     PISSN: 16433165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Grupa Robocza Zalecenia postepowania diagnostycznego i leczniczego w osteoporozie. Obnizenie czȩstości zlamań poprzez efektywna̧ profilaktykȩ i leczenie. Terapia 2007; 9: 1-39.
2. Thrailkill KM, Lumpkin CK, Bunn RC. et al. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab 2005; 289: E735-E745.
3. Strojek K. Etiopatogeneza cukrzycy. In: Diabetologia. Praktyczny poradnik. Termedia Wydawnictwo Medyczne, Poznań 2007; 19-25.
4. Valerio G, Del Puente A, Esposito-del Puente A. et al. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 2002; 58: 266-272.
5. Strotmeyer ES, Cauley JA, Orchard TJ. et al. Middle-aged premenopausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. Diabetes Care 2006; 29: 306-311.
6. Brown SA, Sharples JL. Osteoporosis: An under-appreciated complication of diabetes. Clin Diabetes 2004; 22: 10-20.
7. Hampson G, Evans C, Petitt RJ. et al. Bone mineral density, collagen type 1 α 1 genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 1998; 41: 1314-1320.
8. Hauache OM, Lazaretti-Castro M, Andreoni S. et al. Vitamin D receptor gene polymorphism: correlation with bone mineral density in Brazilian population with insulin-dependent diabetes mellitus. Osteoporos Int 1998; 8: 204-210.
9. Galluzzi F, Stagi S, Salti R. et al. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol 2005; 153: 879-885.
10. Rasmussen LM, Tarnow L, Hansen TK. et al. Plasma osteoprotegerin levels are associated with glycaemic status. systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154: 75-81.
11. Haffner SM, Bauer RL. Excess androgenesity only partially explains the relationship between obesity and bone density in premenopausal women. Int J Obes Relat Metab Disord 1992; 16: 869-874.
12. Cirmanová V, Bayer M, Stárka L. et al. The effect of leptin on bone - an evolving concept of action. Physiol Res 2008; PMID: 18271682 (Epub ahead of print).
13. Iliac J, Kovacev B. Diabetic osteopathy. Med Pregl 2005; 58: 147-152.
14. Yamagishi S, Nakamura K, Inoue H. Possible participation of advance glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 2005; 65: 1013-1015.
15. Strotmeyer ES, Cauley JA, Orchard TJ. et al. Middle-aged premenopausal women with type 1 diabetes have lower bone mineral density and calcaneal quantitative ultrasound than nondiabetic women. Diabetes Care 2006; 29: 306-311.
16. Holmberg AH, Nilsson PM, Nilsson JA. et al. The association between hyperglycemia and fracture risk in middle age. A prospective, population-based study of 22,444 men and 10,902 women. J Clin Endocrinol Metab 2008; 93: 815-822.
17. Suzuki K, Sugimoto C, Takizawa M. et al. Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res Clin Pract 2000; 48: 185-191.
18. Giurato L, Uccioli L. The diabetic foot: Charcot joint and osteomyelitis. Nuclear Medicine Communications 2006; 9: 745-749.
19. Petrova NL, Foster AVM, Edmonds ME. et al. Calcaneal bone mineral density in patients with Charcot neuropatic osteoarthropathy: differences between type 1 and type 2 diabetes. Diabetic Med 2005; 6: 756-761.
20. Brown IR, Mc Bain AM, Chalmers J. et al. Sex difference in the relationship of calcium and magnesium excretion to glycaemic control in type 1 diabetes mellitus. Clin Chim Acta 1999; 283: 119-128.
21. De Luis Roman DA, Aller R, Perez Castrillon JL. et al. Effects of dietary intake and life style on bone density in patients with diabetes mellitus type 2. Ann Nutr Metab 2004; 48: 141-145.
22. Rakel A, Sheehy O, Rahme E. et al. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 2008; 26: (Epub ahead of print).
23. Janghorbani M, Feskanich D, Willett WC. et al. Prospective study of diabetes and risk of hip fracture. The Nurses' Health Study. Diabetes Care 2006; 29: 1573-1578.
24. Janghorbani M, Van Dam RM, Willett WC. et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
25. Strotmeyer ES, Cauley JA, Schwartz AV et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging and body composition study. Arch Intern Med 2005; 165: 1612-1617.
26. Lipscombe LL, Jamal SA, Booth GL. et al. The risk of hip fracture in older Individuals with diabetes. A population-based study. Diabetes Care 2007; 30: 835-841.
27. Soroceanu MA, Miao D, Bai XY. et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004; 183: 203-216.
28. Kahn SE, Haffner SM, Heise MA. et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006; 3555: 2427-2443.
29. Monami M, Cresci B, Colombini A. et al. Bone fractures and hypoglycemic treatment in type 2 diabetes patients: a case-control study. Diabetes Care 2008; 31: 199-203.
30. Di Cesar DJ, Ploutz-Snyder R, Weinstock R.S. et al. Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care 2006; 29: 174.
31. Suzuki A, Kotake M, Ono Y. et al. Hypovitaminosis D in type 2 diabetes mellitus: Association with microvascular complications and type of treatment. Endocr J 2006; 53: 503-510.
32. Keegan THM, Schwartz AV, Bauer DC. et al. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women. The Fracture Intervention Trial. Diabetes Care 2004; 27: 1547-1553.
33. Grey A, Reid IR. Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2006; 2: 77-86.
34. Mahakala A, Thoutreddy S, Kleerekoper M. Prevention and treatment of postmenopausal osteoporosis. Treat Endocrinol 2003; 2: 331-345.